Travere Therapeutics NASDAQ:TVTX Chief Executive Officer Eric M. Dube completed a pair of linked equity transactions on April 1, 2026, selling 60,000 shares of common stock for approximately $1.8 million and exercising options to acquire 60,000 additional shares.
The reported disposition was executed in two separate tranches. The first tranche involved 34,902 shares sold at a weighted average price of $30.55, with sales occurring within a range of $30.13 to $31.07. The second tranche comprised 25,098 shares sold at a weighted average price of $31.46, with individual sale prices falling between $31.15 and $31.67. In aggregate, the cash proceeds from the sales are stated to be about $1.8 million.
Also on April 1, 2026, Dube exercised stock options to acquire 60,000 shares of Travere Therapeutics common stock at an exercise price of $15.46 per share, for a total cost of $927,600.
Following the combination of the exercise and the subsequent open-market sales, Dube is reported to directly own 432,886 shares of Travere Therapeutics.
The company's shares have appreciated strongly over the past year, delivering a 70% total return over that period, and trade at $30.43. That trading level is noted alongside an InvestingPro Fair Value estimate of $33.60, which InvestingPro analysis suggests implies the stock is currently undervalued relative to that Fair Value figure.
The disposition was conducted pursuant to a written plan adopted on June 16, 2025, in a manner the company indicates meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The sales consist of the disposal of shares underlying a stock option grant made to the Reporting Person on January 31, 2020.
Regulatory backdrop
Separately, Travere announced that the U.S. Food and Drug Administration has extended the review timeline for the company's supplemental New Drug Application for Filspari, an investigational treatment for focal segmental glomerulosclerosis, or FSGS. The new Prescription Drug User Fee Act target action date is now April 13, 2026, reflecting a three-month extension following the company's submission of additional information requested by the FDA to further characterize the clinical benefit of Filspari. The FDA characterized its request for additional data as a Major Amendment to the application.
Analyst firm Stifel has reiterated a Hold rating on Travere and maintained a price target of $31.00. The combination of the insider transactions and the FDA filing extension has been described as contributing to regulatory uncertainty for the company as investors await the agency's decision.
Context for investors
The transactions, the company's recent share-price performance, the InvestingPro Fair Value reference, and the Filspari review extension together frame the near-term investor landscape for Travere. The sale was carried out under a pre-established 10b5-1 plan and involved shares tied to an earlier option grant, while the exercise increased Dube's direct share count. The FDA extension sets a fresh PDUFA target action date of April 13, 2026 and followed Travere's provision of additional clinical information requested by the agency.